Labo Euromedis (XPAR:ALEMG) Research & Development: €0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:ALEMG Labo Euromedis XPAR:ALEMG
61 GF Score
Price €4.88
GF Value €4.48
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Labo Euromedis Research & Development?

Labo Euromedis XPAR:ALEMG 61 Research & Development is €0.00 Mil as of Dec. 2025. GuruFocus rates XPAR:ALEMG with a GF Score™ of 61/100 and a GF Value™ of €4.48 (Fairly Valued). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Labo Euromedis's Research & Development for the six months ended in Dec. 2025 was €0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00 Mil.

Labo Euromedis  (XPAR:ALEMG) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Labo Euromedis Research & Development Related Terms

Labo Euromedis Research & Development Historical Data

* Premium members only.

The historical data trend for Labo Euromedis's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Labo Euromedis Research & Development Chart

Labo Euromedis Annual Data
Trend Jul15 Jul16 Jul17 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Labo Euromedis Semi-Annual Data
Jul15 Jan16 Jul16 Jan17 Jul17 Jan18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XPAR:ALEMG
61GF Score
Labo Euromedis XPAR:ALEMG
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Labo Euromedis Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.00 Mil mean?
Labo Euromedis (XPAR:ALEMG) has a Research & Development of €0.00 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Labo Euromedis and its competitors.
Is Labo Euromedis' Research & Development too high?
Labo Euromedis' current Research & Development is €0.00 Mil. Overall, Labo Euromedis has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Labo Euromedis' Research & Development compare to MCK and CAH?
Labo Euromedis' Research & Development of €0.00 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Distribution company?
A good Research & Development depends on the Medical Distribution industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Labo Euromedis and its competitors. Labo Euromedis's current Research & Development is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labo Euromedis stock overvalued right now?
Based on GuruFocus' analysis, Labo Euromedis (XPAR:ALEMG) is currently considered Fairly Valued. The stock's GF Value™ is €4.48, compared to a current price of €4.88 — trading 8.9% above its estimated fair value. The current Research & Development is €0.00 Mil. Labo Euromedis' overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Labo Euromedis (XPAR:ALEMG), the current Research & Development is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Labo Euromedis (XPAR:ALEMG) Overvalued in 2026?

Based on GuruFocus' analysis, Labo Euromedis stock appears to be overvalued. The current stock price of €4.88 is trading 8.9% above its estimated GF Value™ of €4.48. GuruFocus considers Labo Euromedis to be Fairly Valued.

Key valuation signals for XPAR:ALEMG:

  • Research & Development: €0.00 Mil
  • GF Value™: €4.48 vs. price of €4.88 (8.9% above fair value)
  • GF Score™: 61/100 with 6 warning signs

No single metric tells the full story. See the XPAR:ALEMG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Labo Euromedis Business Description

Other Exchanges 0I0L:UK61R:Germany
Address ZI de la Tuilerie, Neuilly-sous-Clermont, FRA, 60290
Labo Euromedis is engaged in medical devices. It is engaged in the design, manufacture, rental and export of medical and surgical equipment and products.
61GF Score

Get the complete analysis for XPAR:ALEMG

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.88
Price
€4.48
GF Value